Q-omics provides the consensus-scored TMEM132B profile across patient tissues and cancer cell-line models. TMEM132B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TMEM132B is differentially expressed in 16, with the highest sampling consensus in THCA. Additionally, TMEM132B protein abundance shows 15,874 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where TMEM132B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM132B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM132B survival associations across molecular data types. TMEM132B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM132B RNA expression–survival associations across cancer types. High TMEM132B expression shows unfavorable associations in BLCA, KIRP and ACC, but favorable associations in HNSC, MESO and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TMEM132B RNA expression.
This table summarizes TMEM132B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM132B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM132B shows lower tumor expression in THCA, COAD, BLCA, HNSC and READ and higher tumor expression in KIRP. The THCA box plot shows higher TMEM132B RNA expression in normal versus tumor tissue (log2 FC = −1.314, t-test p < 0.001).
This table shows molecular features associated with TMEM132B in patient tissues and cancer cell lines. In patient samples, TMEM132B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM132B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BONE.
